OncLive TV

Dr. Shadman on the Exploration of the CAR T-Cell Therapy MB-106 in NHL/CLL

August 8th 2022

Mazyar Shadman, MD, MPH, discusses the exploration of MB-106, a third-generation CD20-targeted autologous CAR T-cell therapy, in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Dr. Hong on the Significance of Larotrectinib in NTRK-Positive NSCLC

August 7th 2022

David S. Hong, MD, discusses the significance of larotrectinib in the treatment of non–small cell lung cancer and other solid tumors harboring NTRK gene fusions.

Dr. Iams on the Evaluation of Sotorasib in KRAS G12C–Mutant Solid Tumors

August 7th 2022

Wade T. Iams, MD, discusses the evaluation of sotorasib in KRAS G12C–mutant solid tumors, including non–small cell lung cancer.

Dr. Tilly on Pola-R-CHP in an Asia Subpopulation of Patients With DLBCL

August 5th 2022

Hervé Tilly, MD, PhD, discusses the efficacy of polatuzumab vedotin-piiq plus rituximab, cyclophosphamide, doxorubicin, and prednisone in an Asia subpopulation of patients with diffuse large B-cell lymphoma.

Dr. Maude on Safety of Tisagenlecleucel in Pediatric B-ALL

August 5th 2022

Shannon L. Maude, MD, PhD, discusses notable long-term safety data with tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia.

Dr. Leleu on the Future of Later-Line Therapy in Multiple Myeloma

August 4th 2022

Xavier Leleu, MD, PhD, discusses how the declining prognosis of patients with multiple myeloma correlates with line of therapy and time after diagnosis, highlighting an unmet need for more effective later-line therapies in this population.

Dr. Seedor on Treatment Sequencing in Metastatic Melanoma

August 4th 2022

Rino S. Seedor, MD, discusses findings from the phase 3 DREAMseq trial, which solidified up-front immunotherapy followed by targeted therapy upon progression as a standard of care in patients with BRAF V600–mutant metastatic melanoma.

Dr. Ready on Leveraging Nivolumab/Ipilimumab Plus Chemotherapy in NSCLC

August 3rd 2022

Neal Edward Ready, MD, PhD, discusses factors to consider when deciding when the use the regimen of nivolumab and ipilimumab plus chemotherapy in metastatic non–small cell lung cancer.

Dr. Carrizosa on the Prevalence of NRG1 Gene Fusions in Solid Tumors

August 3rd 2022

Daniel Carrizosa, MD, MS, discusses the prevalence of NRG1 gene fusions in solid tumors.

Dr. Maddocks on the Investigation of Noncovalent BTK Inhibitors in MCL

August 3rd 2022

Kami J. Maddocks, MD, discusses the investigation of noncovalent BTK inhibitors in mantle cell lymphoma.

Dr. Spira on the Evaluation of Tusamitamab Ravtansine Plus Pembrolizumab in NSCLC

August 3rd 2022

Alexander I. Spira, MD, PhD, FACP, discusses the exploration of the antibody-drug conjugate tusamitamab ravtansine with pembrolizumab in patients with non–small cell lung cancer.

Dr. Lunning on Trials Evaluating BTK Inhibitors in CLL

August 3rd 2022

Matthew A. Lunning, DO, FACP, discusses trials evaluating BTK inhibitors in chronic lymphocytic leukemia.

Dr. Kumar on Treatment Options for Patients Who Progress on a BTK Inhibitor in MCL

August 3rd 2022

Anita Kumar, MD, discusses treatment options for patients with mantle cell lymphoma who progress on BTK inhibitors.

Dr. Borghaei on the Efficacy of Nivolumab/Ipilimumab in STK11/KEAP1-Mutated NSCLC

August 2nd 2022

Hossein Borghaei, DO, MS, discusses the investigation of nivolumab plus ipilimumab and chemotherapy in patients with metastatic non–small cell lung cancer.

Dr. Ligresti on the Need for Screening in Pancreatic Cancer

August 1st 2022

Rosario Ligresti, MD, discusses the need for screening in pancreatic cancer. 

Dr. Slotky on Evolving Treatment with Stem Cell Transplants in Multiple Myeloma

August 1st 2022

Horton on Addressing the Equity Gap of Genetic Testing in Cancer Care

August 1st 2022

Carrie Horton, MS, CGC, discusses the importance of addressing the equity gap of genetic testing in cancer care.

Dr. Morgensztern on Advances With Amivantamab in NSCLC

July 30th 2022

Daniel Morgensztern, MD, discusses ongoing research with amivantamab-vmjw in non–small cell lung cancer.

Dr. Bazhenova on Larotrectinib and Entrectinib in NTRK Fusion–Positive NSCLC

July 30th 2022

Lyudmila A. Bazhenova, MD, discusses NTRK inhibition with larotrectinib and entrectinib in patients with NTRK fusion–positive non–small cell lung cancer.

Dr. Pegram on the Evolving Treatment Landscape in HER2+ Breast Cancer

July 29th 2022

Mark Pegram, MD, discusses the evolving treatment landscape of HER2-positive breast cancer.